1.what are the conditions of new deal between Aventis 2.will be Anti-gastrin for pancreatic cancer approved in Europe?
The new deal with Aventis is the key point concerning the immediate financing of APHT operations. Second, NDA submission in Europe will be submitted in July or in August 2003 and the approval should be finished till the end of 2003. So we can expect the product will be on the market in EU in the end of the first quarter of 2004.
Now we expect results from U.S.part of CT for AGI for pancreatic cancer and results from clinical trials for colorectal cancer.
The next thing is, the competition in novel cancer therapeutics is huge. My opinion is the future belongs to gene therapy (in combination with RT) despite latest problems with retroviruses.But next 5 years I won�t expect any "gene therapy product" will be a real blockbuster. Immunotherapy is probably the most attractive approach for next 5 years for stock investors!!!